BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35594918)

  • 1. Cyclin D1 Expression and Molecular Genetic Findings in Periocular Histiocytoses and Neoplasms of Macrophage-Dendritic Cell Lineage.
    Milman T; Eiger-Moscovich M; Henry RK; Ida CM; Ruben M; Shields CL; Lally SE; Penne RB; Stefanyszyn MA; Bilyk JR; Rapuano CJ; Rabinowitz M; Eagle RC
    Am J Ophthalmol; 2022 Oct; 242():36-51. PubMed ID: 35594918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte-rich tumours.
    Ungureanu IA; Cohen-Aubart F; Héritier S; Haroche J; Donadieu J; Emile JF
    Histopathology; 2023 Aug; 83(2):320-325. PubMed ID: 37012662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
    Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
    Geerlinks AV; Abla O
    Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous histiocytoses in children.
    Fraitag S; Emile JF
    Histopathology; 2022 Jan; 80(1):196-215. PubMed ID: 34958507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant Histiocytosis Comprises a Phenotypic Spectrum That Parallels the Lineage Differentiation of Monocytes, Macrophages, Dendritic Cells, and Langerhans Cells.
    Ravindran A; Dasari S; Ruan GJ; Artymiuk CJ; He R; Viswanatha DS; Abeykoon JP; Zanwar S; Young JR; Goyal G; Go RS; Rech KL;
    Mod Pathol; 2023 Oct; 36(10):100268. PubMed ID: 37406859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D1 Is Expressed in Neoplastic Cells of Langerhans Cell Histiocytosis but Not Reactive Langerhans Cell Proliferations.
    Shanmugam V; Craig JW; Hornick JL; Morgan EA; Pinkus GS; Pozdnyakova O
    Am J Surg Pathol; 2017 Oct; 41(10):1390-1396. PubMed ID: 28622183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Comparison of recent WHO classification published 2017 and classification of Histiocyte Society published 2016.
    Král Z; Adam Z; Ježová M; Pour L; Krejčí M
    Vnitr Lek; 2020; 66(6):19-27. PubMed ID: 33380149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-regulated kinase pathway activation.
    Garces S; Medeiros LJ; Marques-Piubelli ML; Coelho Siqueira SA; Miranda RN; Cuglievan B; Sriganeshan V; Medina AM; Garces JC; Saluja K; Bhattacharjee MB; Khoury JD; Li S; Xu J; Jelloul FZ; Thakral B; Cameron Yin C
    Hum Pathol; 2022 Mar; 121():36-45. PubMed ID: 34995673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages.
    Durham BH
    Semin Cell Dev Biol; 2019 Feb; 86():62-76. PubMed ID: 29526544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1: potential utility as marker for Langerhans cell histiocytosis.
    Ben Rejeb S; Charfi L; Sahraoui G; Boujelben N; Mrad K; Doghri R
    J Immunoassay Immunochem; 2021 Jul; 42(4):370-379. PubMed ID: 33444078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological significance of cyclin D1 expression in Rosai-Dorfman disease].
    Liu C; Li X; Song GX; Hua HJ; Gong QX; Wang Z; Fan QH
    Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1158-1162. PubMed ID: 33152822
    [No Abstract]   [Full Text] [Related]  

  • 13. OCT2 expression in histiocytoses.
    Ungureanu IA; Cohen-Aubart F; Héritier S; Fraitag S; Charlotte F; Lequain H; Hélias-Rodzewicz Z; Haroche J; Donadieu J; Emile JF
    Virchows Arch; 2023 Jul; 483(1):81-86. PubMed ID: 36754897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.
    Emile JF; Abla O; Fraitag S; Horne A; Haroche J; Donadieu J; Requena-Caballero L; Jordan MB; Abdel-Wahab O; Allen CE; Charlotte F; Diamond EL; Egeler RM; Fischer A; Herrera JG; Henter JI; Janku F; Merad M; Picarsic J; Rodriguez-Galindo C; Rollins BJ; Tazi A; Vassallo R; Weiss LM;
    Blood; 2016 Jun; 127(22):2672-81. PubMed ID: 26966089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nosology and Pathology of Langerhans Cell Histiocytosis.
    Picarsic J; Jaffe R
    Hematol Oncol Clin North Am; 2015 Oct; 29(5):799-823. PubMed ID: 26461144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histiocytosis - cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations.
    Luder CM; Nordmann TM; Ramelyte E; Mühleisen B; Kerl K; Guenova E; Dummer R
    J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):926-934. PubMed ID: 29341328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Central nervous system disorders secondary to histiocytoses: neurodegeneration with potential for improvement].
    Morimoto A; Sakamoto K; Kudo K; Shioda Y
    Rinsho Shinkeigaku; 2024 Feb; 64(2):85-92. PubMed ID: 38281751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
    Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
    Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central Nervous System and Head and Neck Histiocytoses: A Comprehensive Review on the Spectrum of Imaging Findings.
    Hashmi SS; Guha-Thakurta N; Ketonen L; Williams MD; Shah S; Debnam JM
    Neurographics (2011); 2016 Mar; 6(2):114-122. PubMed ID: 30417172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
    Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
    Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.